Opendata, web and dolomites

ColoFast SIGNED

Developing a Non-Invasive Kit for Early Colorectal Cancer Detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ColoFast project word cloud

Explore the words cloud of the ColoFast project. It provides you a very rough idea of what is the project "ColoFast" about.

regulatory    life    kit    avings    validate    sensitivity    detection    acceptance    2021    colofast    quality    huge    people    priorities    reduce    blood    fulfill    worldwide    medical    team    reducing    generation    savings    business    diagnosed    multiplying    japan    give    decreasing    healthcare    unmet    easily    community    treatment    showed    invasive    assisting    earlier    sme    employees    rate    services    profit    biomarkers    agrees    25    turnover    prevented    2020    approved    patients    mortality    majority    screening    look    amadix    commercialization    commercialize    deaths    crc    616m    colorectal    colofasttm    programs    national    care    population    opportunity    global    survival    clinical    strategies    41    profitable    hospitals    189m    clear    benefit    cohorts    expanding    2024    specificity    18    routine    2m    cancer    health    patient    diagnosis    company    prospective    edge    improvements    size    market   

Project "ColoFast" data sheet

The following table provides information about the project.

Coordinator
ADVANCED MARKER DISCOVERY SL 

Organization address
address: CALLE ACERA DE RECOLETOS 2 1 B
city: VALLADOLID
postcode: 47004
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.amadix.com/colofast/
 Total cost 2˙817˙154 €
 EC max contribution 2˙817˙154 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADVANCED MARKER DISCOVERY SL ES (VALLADOLID) coordinator 2˙817˙154.00

Map

 Project objective

Colorectal cancer (CRC) represents one of the most important health problems worldwide. Decreasing the mortality rate by CRC in Europe is a clear unmet need today. Medical community agrees that this number of CRC related deaths could be prevented by adequate screening programs for early detection. European authorities look for new strategies to address the clinical need for early diagnosis of CRC that will reduce patient care associated costs. Potential savings would be achieved if CRC patients were diagnosed earlier. The objective of this proposal is to validate and commercialize a novel, non-invasive, simple to use kit (ColoFastTM), regulatory approved for the diagnosis of CRC in blood. It is based on a new generation of leading-edge biomarkers that showed very high sensitivity and specificity for early detection of CRC in two prospective cohorts. The commercialization of the kit will have clear impact in improving survival of patients and reducing mortality by CRC cancer, with significant costsavings for National Health Services. It will be easily implemented in the clinical routine of the majority of European hospitals, with better acceptance of patients. ColoFast represents a significant business opportunity, addressing a clear unmet medical need in a large and expanding target population of 189M people in Europe in 2020, growing at 25%, with a significant global market of €1,616M in Europe, the US and Japan this year. It will have a huge impact on the growth of a SME as Amadix over the next 10 years, multiplying the team size by five in five years (41 employees in 2020). 2M European people will benefit from the test in 2024. Amadix turnover in 2021 will be €18 m, which will give our company a profit of €7 m in 2021. From this year on the company will be profitable. Overall, ColoFast will reduce mortality rate and treatment cost while improving quality of life in a cost-effective way, assisting also to fulfill European priorities for healthcare improvements.

 Deliverables

List of deliverables.
Research data management plan Documents, reports 2020-01-27 14:54:22
1st Dissemination and Communication Plan: Documents, reports 2020-01-27 14:54:22

Take a look to the deliverables list in detail:  detailed list of ColoFast deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COLOFAST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COLOFAST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More